Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP) (NCT07279948) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)
Brazil477 participantsStarted 2026-06-30
Plain-language summary
A prospective, longitudinal, single-arm interventional study of lung cancer screening.
Who can participate
Age range
50 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
In order, to be eligible for the study, patients must fulfill all the following inclusion criteria:
* Age between ≥50 and ≤80 years.
* Be a current smoker or have quit 15 years ago or less.
* Have participated or are currently participating in smoking cessation program.
* Lifetime smoking exposure equal to or greater than 20 pack-year.
* Provided signed informed consent (ICF)
Exclusion Criteria:
* In order, to be exclude for the study, patients must at least one of the following exclusion criteria:
* Contraindications to the screening examination: (claustrophobic or weighing more than 130 kgs).
* Inability to climb 3 stair steps non-stop (36 steps).
* Disabling dyspnea
* Symptomatic (with signs and symptoms suspicious of breast cancer lung, namely):
* pleuritic chest pain
* rapidly progressive dyspnea of recent onset
* hemoptysis
* unexplained hoarseness, lasting more than 1 month.
* bone pain
* supraclavicular lymphadenopathy or cervical lymphadenopathy persistent
* unexplained weight loss of 5% or more of weight in less than 6 months
* Previous history of malignant neoplasm (excluding non-melanoma skin cancer) diagnosed less than 10 years before the date of the interview;
* Patients with diagnostic of severe psychiatric disease
* Immunosuppressed by illness or drugs.
* Subjected to anterior lung resection even when determined due to an etiology other than malignant neoplasia.
* Person with a s…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
• Proportion of negative cases on screening according to the Lung-RADS classification.